Cannabinoid and Apelin in Treatment of COVID-19

Antinflammatry Effect of Apelin on COVID-19

CBD has been shown to reduce lung inflammation caused by COVID-19 by increasing levels of the apelin peptide. Cannabidiol (CBD) lowers cytokine storm which damages the lungs, the major cause of death in patients. The Mechanism of action is said to be increase in levels of apelin a natural peptide which reduces inflammation.

Apelin is said to be a peptide made by cells found in the heart, lung, brain, fat tissue and blood and is an important regulator in lowering both blood pressure and inflammation. Apelin blood levels have been shown to fall close to zero in acute respiratory distress syndrome (ARDS) models but increased 20 times with CBD.

The essence of this is to improve blood and oxygen flow in the lungs to compensate and to protect. However, in the ARDS model, apelin did not do either, instead a decrease was observed in both the lung tissue and the general circulation – until addition of CBD.

It has been reported that treatment with CBD reduces excessive lung inflammation, encouraging improvements in lung function, healthier oxygen levels and repair of some of the structural damage to the lungs that are classic with ARDS.

Research is on the way to establish whether SARS-CoV-2 or CBD have a direct effect on apelin levels, or if these are downstream consequences. Further steps include better understanding of the interaction between CBD, apelin and SARS-CoV-2 and the reasons for reduction of apelin in the face of the virus and why CBD brings it up.

3 views0 comments